This phenomenon leads to resistance to venetoclax/azacitidine therapy and highlights the importance of including a fatty acid metabolism inhibitor to restore sensitivity to BCL-2 inhibition in AML cells [22]. Here, BCL2 is linked to acute myeloid leukemia.